Ursodeoxycholic Acid Market Size, Share, Trends, Growth and Market Forecast 2023 - 2030

Global Ursodeoxycholic Acid Market is segmented By Type (Synthetic USDA, Extraction USDA), By Application (Pharmacy, Health Products), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis,  2023 - 2030

Ursodeoxycholic Acid Market Overview

Report on Global Ursodeoxycholic Acid by DataM Intelligence estimates the market to grow at a CAGR of 10% during forecast period 2023 - 2030. Ursodeoxycholic Acid usage in chronic cholestatic liver disease is on the rise. Demand from patients suffering from liver disease in Asia Pacific is booming. Competitive rivalry intensifies with AS Grindeks, Erregierre SpA, Daewoong Bio Inc and others operating in the market.

• Ursodeoxycholic acid (UDCA) is a naturally occurring bile used to dissolve gallstones that are rich in cholesterol and cholestatic liver disease.
• The acid is also used to enhance the flow of bile in primary biliary cirrhosis and cystic fibrosis.

Ursodeoxycholic Acid Market Scope and Summary

To Get a Free Sample Click here

Ursodeoxycholic Acid Market Trends and Dynamics

• The rise in cases of gallstone problems and cholestatic liver diseases have increased the demand for ursodeoxycholic acid end-products.
• According to the 2017 Annual Data Report published by the Cystic Fibrosis Foundation, 12.8 percent of individuals are prescribed ursodeoxycholic acid, which is most commonly prescribed to those with abnormal liver function tests or suspected CF liver disease.
• The occurrence of gallstones in women and older adults have driven the demand for ursodeoxycholic acid, as the ursodeoxycholic acid can dissolve the smaller stones made primarily of cholesterol. Ursodeoxycholic acid also reduces the absorption of cholesterol from the intestinal tract.
• The side effects occurring in patients, including diarrhea, indigestion, headache, and nausea or vomiting might hamper the growth of the market.
• A recent study published by the National Center for Biotechnology Information (NCBI) showed the occurrence of diarrhea in patients prescribed with UDCA in the range of 3-7%. The other side-effects such as back pain, fever, cough, and hair loss might also act as market deterrents

Ursodeoxycholic Acid Market Segmentation Analysis

• The ursodeoxycholic acid market is segmented by type into synthetic USDA and extraction USDA. The synthetic USDA end-products are expected to dominate the market share during the forecast period, with the segment value at 317 USD million in 2017.
• The synthetic acid is widely used in the treatment of gallstones and is marketed under multiple trade names such as Actibile, Actigall, Ursolic, Ursofalk, and Steiner. For instance, in May 2016, the U.S. Food and Drug Administration granted accelerated approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA.
• By application, the market is categorized into pharmacy and health products. The end products are most widely used in health products, with the segment dominating the market share in 2017 at 299 USD million.
• The end-products in health products come in the form of tablets and capsules which are marketed by pharmaceutical companies as alternatives to the surgical procedure of gallstones operation.

Global Ursodeoxycholic Acid Market Geographical Share

The global ursodeoxycholic acid market is segmented geographically by region into North America, South America, Europe, Asia-Pacific, and Rest of the World (RoW).

The Asia-Pacific region is the leading geographical segment by market revenue owing to the rise in production and product sales of the end-products in leading countries such as China and Japan.

The number of patients and prevalence of primary biliary cholangitis, the chronic cholestatic liver disease is increasing in China, with the majority of patients treated with ursodeoxycholic acid medical therapy, thus driving demand for the UDCA market in the region.

Ursodeoxycholic Acid Companies and Competitive Landscape

The market for ursodeoxycholic acid is moderately competitive, with the development of end-products and elimination of end-products still at a nascent stage.

The key players of the market include Abil Chempharma Private Limited, AS Grindeks, Biotavia Labs Pvt Ltd., Mitsubishi Tanabe Pharma Corporation, and ICE. The companies focus on the expansion of product portfolio and business reach through mergers and acquisitions.

For instance, in June 2016, Retrophin, Inc. announced the signing of a definitive agreement to purchase the rights, titles, and ownership of a liquid formulation of ursodeoxycholic acid from Asklepion Pharmaceuticals, LLC.

Report Insights

The synthetic UDCA market segment is expected to continue its domination by market share during the forecast period owing to the development and innovation of the synthesis techniques involved in the manufacturing of synthetic UDCA.

Asia-Pacific is the leading geographical segment due to the rise in production and product sales of the end-products in leading countries such as China and Japan.

The companies are focused on the launch of new products to strengthen market position and increase company revenue. For instance in May 2015, AS Grindeks announced the introduction of the final dosage form (capsule) of Ursodeoxycholic acid (UDCA) and started its export to Russia and Georgia.

The scope of the Report

• The report covers the factors impacting the market, Porter 5 Forces, Competitive Scenario, Product Benchmarking, and company profiles. Ursodeoxycholic Acid Market is segmented by type into Synthetic USDA and Extraction USDA. By application, the global Ursodeoxycholic Acid market is segmented into pharmacy and health products.

• Geographically, the market is segmented into North America, South America, Europe, Asia Pacific and Rest of the World.

Trending Topics

Pharmacy Automation Systems Market

Pharmaceutical Logistics Market

Pharmaceutical Vials Market